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Nine years ago, at the European Society of Car-
diology Meeting 2009 in Barcelona, the first trial 
investigating a modern non-vitamin K antagonist 
oral anticoagulants (NOACs) in atrial fibrillation 
(AF) — the Re-LY trial comparing dabigatran to 
warfarin — was presented and published simultane-
ously in the ”New England Journal of Medicine” [1]. 
Re-LY was followed by ROCKET-AF (with rivar-
oxaban) [2], ARISTOTLE (with apixaban) [3] and 
ENGAGE AF-TIMI 48 (with edoxaban) [4]. It was 
the start of a veritable paradigm shift in the preven-
tion of stroke in AF; similar (if not better) efficacy 
with better safety (particularly regarding the most 
feared complication of intracranial hemorrhage) was 
nothing anybody would have anticipated beforehand.
Yet, the advent of these new drugs also meant 
the advent of new questions, many of which could 
not (yet) be answered readily by the landmark 
randomized clinical trials. What is the best “start-
up” scheme if I want to newly start a patient on 
a NOAC? How do I best switch a patient from vitamin 
K antagonists (VKA)? How do we deal with dosing 
errors? What do we have to do in case of bleeding 
(the fear of the lack of a rapidly acting, specific 
antidote was enormous in the early days of NOACs 
— thereby ignoring that a rapidly acting, specific 
antidote also does not exist for VKA…)? When 
should we stop/when should we re-initiate NOACs 
around invasive procedures and operations? Can 
we cardiovert a patient under NOAC therapy? And 
many others. These questions, arising out of situ-
ations from “daily clinical practice” demanded for 
practical answers. The idea to the first “Practical 
Guide” of the European Heart Rhythm Associa-
tion (EHRA) was born and ultimately realized by 
Hein Heidbüchel and his co-workers in 2013 [5]. 
The “EHRA Practical Guide” rapidly became 
a point of reference for many healthcare providers, 
from general practitioners to cardiologists, from 
specialized nurses to surgeons, when practical 
daily-life questions arose for which there was no 
answer (yet) from clinical trial data. In addition to 
these practical advice, the first edition of the Guide 
also already featured the “EHRA universal NOAC 
card”. Purpose-equivalent to the international 
normalized ratio booklet of patients under VKA 
therapy, the main goals of this card were to inform 
healthcare providers of the therapy the patient is 
taking, especially in emergency situations where 
the patient may be unable to answer and, likely 
equally if not more important, to sensitize patients 
and make them aware that although they are not 
(or no longer) on VKA, this new medication is (a) 
important and should therefore (b) not be forgotten. 
Over the years, several of the “data holes” 
which were dealt with initially in the Practical 
Guide 2013 were filled — e.g., with the first studies 
investigating the possibility to perform cardiover-
sions in patients on NOACs, as well as important 
subanalyses on the use of NOACs in renal dysfunc-
tion. In addition, the availability of edoxaban after 
its presentation in November 2013 demanded for 
its inclusion in the Practical Guide. As such, an 
“Update” was published in 2015 acknowledging 
the developments in this rapidly moving field [6].
With the ever growing increase in the use of 
NOACs and — fortunately — undamped research 
interest in further refining the value and use of 
these drugs also in more complex scenarios, it 
was a matter of time until also the 2015 Update 
would become partially ‘outdated’. As a result, 
another “update” was initiated in the summer of 
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2017. However, during the planning phase it rapidly 
became clear that a simple “update” would likely 
not suffice this time given the exponential growth 
in knowledge and experience. As such, a fully re-
worked and expanded version of the EHRA Practi-
cal Guide was initiated and ultimately published in 
March 2018 (including 476 references, as compared 
to 101 in the 2013 edition) [7]. In the current issue 
of the “Cardiology Journal”, Tomaszuk-Kazberuk et 
al. [8] summarize the main recommendations from 
this work. Several chapters were re-written there-
by including newly available study data, such as the 
management of bleeding complications (with idaru-
cizumab available since > 1 year, and andexanet 
alpha just around the corner) [9], the management 
of patients with AF and coronary artery disease 
(with PIONEER-AF [10] and Re-DUAL PCI [11] 
published, and ENTRUST and AUGUSTUS 
soon to be finished), and the management of an 
acute stroke in patients on NOACs (including the 
possibility to perform thrombolysis in selected 
individuals). At the same time, new and partially 
controversial issues were included such as “How to 
measure anticoagulant effect of NOACs” as well as 
a chapter on the rare indications, precautions, and 
potential pitfalls of plasma level measurements. 
As we get more and more comfortable with 
the use of NOACs, many of the initially open ques-
tions could be answered. At the same time, we are 
moving out of our comfort zone and into treating 
more and more difficult patients. As a result, new 
questions arise: How can we use NOACs in severe 
renal insufficiency (and on dialysis)? What is the 
final verdict on triple therapy; will we need it at all, 
if so for whom? Will plasma level measurements 
really be of help — in emergency situations, in the 
peri-operative setting, in very special situations 
such as severe over- or underweight? And many 
more… it is highly likely that we will see some 
answers over the next years — followed for sure 
by a new version of the EHRA Practical Guide to 
keep on providing practical answers to practical 
questions in order to improve and optimize stroke 
prevention for the many patients with AF. It is 
a complex topic, with not a lot of easy answers; but 
clearly worthwhile investing time and effort into as 
the impact of correct and adequate anticoagulantion 
for our patients will likely be substantial. 
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